Rani Therapeutics (RANI) Competitors $0.48 -0.01 (-2.20%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$0.49 +0.01 (+2.25%) As of 09/25/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RANI vs. CYBN, LFVN, AVTX, NKTX, MCRB, ACTU, CRDF, SKYE, FBRX, and KALAShould you be buying Rani Therapeutics stock or one of its competitors? The main competitors of Rani Therapeutics include Cybin (CYBN), Lifevantage (LFVN), Avalo Therapeutics (AVTX), Nkarta (NKTX), Seres Therapeutics (MCRB), Actuate Therapeutics (ACTU), Cardiff Oncology (CRDF), Skye Bioscience (SKYE), Forte Biosciences (FBRX), and KALA BIO (KALA). These companies are all part of the "pharmaceutical products" industry. Rani Therapeutics vs. Its Competitors Cybin Lifevantage Avalo Therapeutics Nkarta Seres Therapeutics Actuate Therapeutics Cardiff Oncology Skye Bioscience Forte Biosciences KALA BIO Cybin (NYSE:CYBN) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations. Which has preferable valuation and earnings, CYBN or RANI? Rani Therapeutics has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCybinN/AN/A-$57.88M-$4.60-1.27Rani Therapeutics$1.03M33.44-$30.02M-$0.91-0.53 Which has more risk and volatility, CYBN or RANI? Cybin has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500. Do insiders and institutionals have more ownership in CYBN or RANI? 17.9% of Cybin shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 15.0% of Cybin shares are owned by company insiders. Comparatively, 45.1% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor CYBN or RANI? In the previous week, Cybin had 3 more articles in the media than Rani Therapeutics. MarketBeat recorded 4 mentions for Cybin and 1 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 1.89 beat Cybin's score of 0.50 indicating that Rani Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Cybin Positive Rani Therapeutics Very Positive Is CYBN or RANI more profitable? Cybin's return on equity of -37.58% beat Rani Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CybinN/A -37.58% -36.59% Rani Therapeutics N/A -1,258.76%-97.97% Do analysts rate CYBN or RANI? Cybin currently has a consensus price target of $85.00, indicating a potential upside of 1,350.51%. Rani Therapeutics has a consensus price target of $7.33, indicating a potential upside of 1,430.33%. Given Rani Therapeutics' higher possible upside, analysts clearly believe Rani Therapeutics is more favorable than Cybin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cybin 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Rani Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryRani Therapeutics beats Cybin on 8 of the 14 factors compared between the two stocks. Get Rani Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RANI vs. The Competition Export to ExcelMetricRani TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.22M$3.13B$5.75B$10.39BDividend YieldN/A2.39%5.75%4.64%P/E Ratio-0.5320.6375.7726.11Price / Sales33.44442.69544.62124.93Price / CashN/A44.6737.5461.24Price / Book7.999.6212.876.30Net Income-$30.02M-$52.73M$3.29B$271.03M7 Day Performance-6.93%1.81%0.28%-0.14%1 Month Performance-19.19%5.50%2.87%5.82%1 Year Performance-77.29%18.12%65.66%27.63% Rani Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RANIRani Therapeutics3.3036 of 5 stars$0.48-2.2%$7.33+1,430.3%-76.7%$35.22M$1.03M-0.53110Positive NewsCYBNCybin2.7046 of 5 stars$6.01-1.3%$85.00+1,314.3%N/A$141.78MN/A-1.3750LFVNLifevantage3.9615 of 5 stars$10.68-4.0%$30.50+185.6%-15.7%$141.25M$228.53M14.43260AVTXAvalo Therapeutics3.9336 of 5 stars$10.14-4.8%$30.00+195.9%+27.3%$140.14M$440K0.0040Positive NewsNKTXNkarta2.1333 of 5 stars$1.97flat$13.60+590.4%-57.4%$139.92MN/A-1.33140Positive NewsMCRBSeres Therapeutics1.7468 of 5 stars$15.69-1.4%$73.67+369.5%+3.2%$139.29M$126.32M-3.41330Analyst ForecastACTUActuate Therapeutics2.3901 of 5 stars$7.00+4.9%$20.33+190.5%+14.7%$138.60MN/A0.0010Trending NewsAnalyst ForecastAnalyst RevisionCRDFCardiff Oncology2.3115 of 5 stars$2.04-0.5%$10.63+420.8%-23.9%$136.38M$680K-2.3420Positive NewsSKYESkye Bioscience1.8162 of 5 stars$4.07-4.2%$15.50+280.8%-7.5%$131.70MN/A-3.8411High Trading VolumeFBRXForte Biosciences3.1509 of 5 stars$11.48+8.7%$68.00+492.3%+115.9%$131.29MN/A-0.705High Trading VolumeKALAKALA BIO4.1562 of 5 stars$19.25+3.4%$21.75+13.0%+233.7%$130.73M$3.89M-2.8430 Related Companies and Tools Related Companies CYBN Alternatives LFVN Alternatives AVTX Alternatives NKTX Alternatives MCRB Alternatives ACTU Alternatives CRDF Alternatives SKYE Alternatives FBRX Alternatives KALA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RANI) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredChina Targets MAGA In Stealth Trade War TacticsChina is deliberately targeting the economic backbone of conservative America - The very industries that supp...Goldco Precious Metals | SponsoredCollege grad makes $64,000 a monthNothing hurts like a missed opportunity... And with AI stocks like Nvidia, Palantir, and Oracle continuing...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rani Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RANI Stock Alerts